<div id="readability-page-1"><p>InflaRx (NASDAQ:IFRX - Get Free Report) issued its quarterly earnings data on Wednesday. The company reported ($0.09) earnings per share for the quarter, beating analysts' consensus estimates of ($0.17) by $0.08, FiscalAI reports.</p><h2>InflaRx Trading Up 26.9%</h2><p>Shares of NASDAQ:IFRX traded up $0.53 during trading on Wednesday, reaching $2.50. The company's stock had a trading volume of 18,208,689 shares, compared to its average volume of 1,612,826. InflaRx has a 12 month low of $0.71 and a 12 month high of $2.86. The firm's 50 day simple moving average is $1.16 and its two-hundred day simple moving average is $1.12. The stock has a market capitalization of $180.73 million, a PE ratio of -3.29 and a beta of 2.42. </p><h2>Institutional Inflows and Outflows</h2><p>Institutional investors have recently made changes to their positions in the business. Cubist Systematic Strategies LLC lifted its holdings in shares of  InflaRx by 33.9% in the 1st quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company's stock valued at $31,000 after acquiring an additional 7,616 shares during the last quarter.  HRT Financial LP bought a new position in shares of  InflaRx in the 4th quarter valued at about $47,000.  Insigneo Advisory Services LLC bought a new position in shares of  InflaRx in the 4th quarter valued at about $61,000.  Quadrature Capital Ltd bought a new position in shares of  InflaRx in the 4th quarter valued at about $104,000.  Finally, XTX Topco Ltd bought a new stake in  InflaRx in the fourth quarter worth about $135,000. Institutional investors own  42.39% of the company's stock. </p><h2>Wall Street Analyst Weigh In</h2><p>A number of research analysts have recently weighed in on the company. Oppenheimer assumed coverage on InflaRx in a research report on Friday, April 24th. They set an &#34;outperform&#34; rating and a $5.00 price objective for the company. Guggenheim  restated a &#34;buy&#34; rating and set a $14.00 price objective on shares of InflaRx in a research report on Tuesday, April 21st. Finally, Weiss Ratings  restated a &#34;sell (d-)&#34; rating on shares of InflaRx in a research report on Friday, March 27th. Four investment analysts have rated the stock with a Buy rating, one  has given a Hold rating and one  has assigned  a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of &#34;Moderate Buy&#34; and an average target price of $5.80.</p><p><b>Get Our Latest Stock Report on IFRX</b></p><h2>InflaRx Company Profile</h2> (Get Free Report)<p>InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company's lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.  </p><p>Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than InflaRx</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SUZSWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SUZSWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in InflaRx Right Now?</h2><p>Before you consider InflaRx, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InflaRx wasn't on the list.</p><p>While InflaRx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

IFRX

IBBQ

<p>InflaRx (NASDAQ:IFRX) reported quarterly earnings of ($0.09) EPS, surpassing estimates of ($0.17) by $0.08. Following the announcement, shares rose 26.9% to $2.50. Institutional investors hold 42.39% of the stock, with several recent acquisitions. Analysts have mixed ratings, with an average target price of $5.80. InflaRx focuses on developing therapies targeting the complement system, particularly for autoimmune and inflammatory diseases.</p>

Market Beat

InflaRx NV

InflaRx (NASDAQ:IFRX) Posts Earnings Results, Beats Estimates By $0.08 EPS